BMI View: The incumbent Liberal-National coalition's victory in Australia's federal elections will not bring
about a clear policy direction for the healthcare sector. While the government has a fresh mandate to enact
its policies, it is considerably weaker from the pr ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landsc ..."
BMI View: Drugmakers operating in Australia will face an increasingly challenging business environment
as the Sixth Pharmacy Community Agreement's measures come into effect. This includes a 5% price cut to
medicines listed on the F1 formulary for more than five years, ..."
BMI View: As the Australian government continues to focus on cost containment while at the same time
increasing the population's access to innovative medicines, companies will increasingly need to justify the
price of their treatments by demonstrating their value to t ..."
BMI View: The prevailing trend of austerity targeting pharmaceuticals and healthcare spending in
Australia will continue to weigh on the country's attractiveness to innovative drugmakers. On top of this,
ongoing political instability and policy uncertainty have modera ..."
BMI View: The Australian pharmaceutical market is expected to continue on a moderate growth trajectory
over our forecast period. This is mainly explained by rising chronic disease burden as well as government
funding to list new medicines under the Pharmaceutical Bene ..."
BMI View: The domestic backlash against the Australian government's budget saving efforts focusing on
areas of the healthcare sector, including general practice copayments, will translate into additional
incentives for the government to place pressure on pharmaceutica ..."
BMI View: Recent attempts by the Australian government to introduce cost saving changes to the Medicare
program have been met with opposition. Most have now been shelved. With healthcare costs growing at a
'rapid and unsustainable rate', as reported by Health Minister ..."
BMI View: The Australian government will continue to use drug price controls as a means to reduce
healthcare expenditure. Our view is based on the government's runaway budget deficit and the inevitable
increased demand for medicines as the population ages and incidenc ..."
BMI View: Over 300 drug formulations listed on the Pharmaceutical Benefits Scheme (PBS) will be subject
to price reduction from October 1 2014, following the first simplified price disclosure (SPD) cycle in
Australia. As a result, the prices of the affected drugs will ..."